17 Aug VSIQQ® (Brolucizumab) – A Requirement to Discontinue Treatment with Vsiqq® in Patients who Develop Retinal Vasculitis and/or Retinal Vascular Occlusion, Typically in the Presence of Intraocular Inflammation
Posted at 11:43h
in
Novartis, as directed by the South African Health Products Regulatory Authority (SAHPRA), would like to inform you about the requirement to discontinue treatment with Vsiqq® in patients who develop retinal vasculitis and/or retinal vascular occlusion. Retinal vasculitis and retinal vascular occlusion are immune-mediated events, which typically occur in the presence of intraocular inflammation.
2021 Nov
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
24/11/2021
File Type:
pdf
Category:
Communication To Health Care Professionals